AtriCure, Inc. (ATRC) has a MoatMap StockRank of 41/100 based on Quality (60/100), Value (30/100), and Momentum (38/100) factor scores. The current signal is HOLD. AtriCure is a solid medical device company focused on atrial fibrillation, but it lacks direct alignment with our core 18-month macro themes.
AtriCure, Inc. is a medical device company dedicated to developing, manufacturing, and selling products for the treatment of atrial fibrillation (Afib) and other cardiac arrhythmias. The company is a recognized market leader in surgical Afib solutions, offering a comprehensive portfolio of ablation systems and cryoablation products. AtriCure's competitive advantage stems from its strong intellectual property, extensive clinical evidence, and established surgeon relationships in this specialized field.
| Price | $27.30 |
| Market Cap | $1.4B |
| P/E (Forward) | 78.20 |
| Price/Book | 2.81 |
| Return on Equity | -1.0% |
| Return on Invested Capital | -0.7% |
| Debt/Equity | 15.24 |
| Gross Margin | 75.6% |
| Operating Margin | 0.4% |
| Revenue Growth | 14.3% |
| Free Cash Flow | $41M |
AtriCure, Inc. operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (United States).